Prognostic determinants in prostate cancer

Cancer Journal

Volumn 17, Issue 6, 2011, Pages 429-437

  Martin, Neil E ^a   Mucci, Lorelei A ^b   Loda, Massimo ^a   DePinho, Ronald A ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

gene expression signatures; immunohistochemistry; Prognosis; prostate

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID SYNTHASE; KI 67 ANTIGEN; MICRORNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UVOMORULIN; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER GRADING; CANCER INVASION; CELL CYCLE PROGRESSION; GLEASON SCORE; HEREDITY; HUMAN; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 83755196822     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31823b042c     Document Type: Review

References (112)

1. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713-2719. (Pubitemid 38725420)
2. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781-789. (Pubitemid 34988336)
3. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011; 364:1708-1717.
4. Shao Y-H, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101: 1280-1283.
5. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
6. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360: 1310-1319.
7. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostatecancer mortality in a randomized European study. N Engl J Med. 2009; 360:1320-1328.
8. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725-732.
9. Stephenson AJ, KattanMW, Eastham JA, et al. Prostate cancerYspecific mortality after radical prostatectomy for patients treated in the prostatespecific antigen era. J Clin Oncol. 2009;27:4300-4305.
10. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974. (Pubitemid 28445094)
11. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-1507. (Pubitemid 29220858)
12. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771. (Pubitemid 28259189)
13. Blute ML, Bergstralh EJ, Iocca A, et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001;165: 119-125.
14. Partin AW, Piantadosi S, Sanda MG, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 1995;45:831-838.
15. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-383.
16. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: longterm cancer control and recovery of sexual and urinary function ("trifecta" ). Urology. 2005;66:83-94. (Pubitemid 41356564)
17. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancerYspecific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383. (Pubitemid 37220457)
18. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597. (Pubitemid 29211767)
19. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58-64.
20. Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185: 869-875.
21. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248-1253. (Pubitemid 41535365)
22. Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009;27:3459-3464.
23. Andren O, Fall K, Franzen L, et al. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 2006;175:1337-1340.
24. Smith EB, Frierson HF Jr, Mills SE, et al. Gleason scores of pros tate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer. 2002;94:2282-2287. (Pubitemid 34411988)
25. Walz J, Chun FK, Klein EA, et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol. 2009;181:601-607; discussion 7-8.
26. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
27. D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447. (Pubitemid 41124176)
28. Villers A, McNeal JE, Redwine EA, et al. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol. 1989;142:763-768. (Pubitemid 19226718)
29. Nelson CP, Dunn RL, Wei JT, et al. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. Urol Oncol. 2003;21:213-218. (Pubitemid 36723710)
30. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol. 2004; 171:1132-1136. (Pubitemid 38327542)
31. Harnden P, Shelley MD, Clements H, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer. 2006;109:13-24.
32. Ng JC, Koch MO, Daggy JK, et al. Perineural invasion in radical prostatectomy specimens: lack of prognostic significance. J Urol.2004;172:2249- 2251. (Pubitemid 39507501)
33. Boorjian SA, Karnes RJ, Rangel LJ, et al. Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008;179:1354-1360; discussion 60-61.
34. Korets R, Motamedinia P, Yeshchina O, et al. Accuracy of the Kattan nomogram across prostate cancer risk-groups. BJU Int. 2011;108:56-60.
35. Ludwig JA,Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-856. (Pubitemid 41746029)
36. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869-873.
37. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470:214-220.
38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100: 57-70. (Pubitemid 30046295)
39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
40. Shukla-Dave A, Hricak H, Ishill N, et al. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res. 2009;15:3842-3849.
41. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgenreceptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393-1398.
42. Pollack A, DeSilvio M, Khor LY, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol. 2004;22: 2133-2140. (Pubitemid 41095146)
43. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996;156:1064-1068. (Pubitemid 26269830)
44. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596-4599. (Pubitemid 47037039)
45. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008;27:253-263.
46. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69:1400-1406.
47. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res. 2003;9:1474-1479. (Pubitemid 36418404)
48. McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999;59:4291-4296. (Pubitemid 29418745)
49. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004;10: 6572-6578. (Pubitemid 39346553)
50. Li R, Dai H, Wheeler TM, et al. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Clin Cancer Res. 2009;15:3568-3573.
51. Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res. 2007;13:6579-6584. (Pubitemid 350206791)
52. Moul JW, Friedrichs PA, Lance RS, et al. Infrequent RAS oncogene mutations in human prostate cancer. Prostate. 1992;20:327-338.
53. Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009;101:519-532.
54. Nguyen PL, Ma J, Chavarro JE, et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010;28:3958-3964.
55. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-629.
56. Lee CT, Capodieci P, Osman I, et al. Overexpression of the cyclindependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res. 1999;5:977-983. (Pubitemid 29233210)
57. Aaltomaa S, Lipponen P, Eskelinen M, et al. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate. 1999; 39:8-15. (Pubitemid 29143103)
58. Kuczyk M, Machtens S, Hradil K, et al. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer. 1999;81:1052-1058. (Pubitemid 29516151)
59. Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002;8:3419-3426. (Pubitemid 35340716)
60. Sato K, Qian J, Slezak JM, et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst. 1999;91:1574-1580. (Pubitemid 29457963)
61. Prowatke I, Devens F, Benner A, et al. Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer. 2007;96:82-88. (Pubitemid 46094643)
62. Pomerantz MM, Beckwith CA, Regan MM, et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009;69:5568-5574.
63. Fordyce CA, Heaphy CM, Joste NE, et al. Association between cancerfree survival and telomere DNA content in prostate tumors. J Urol. 2005;173:610-614.
64. Bauer JJ, Sesterhenn IA, Mostofi KF, et al. P53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res. 1995;1:1295-1300.
65. Concato J, Jain D, Uchio E, et al. Molecular markers and death from prostate cancer. Ann Intern Med. 2009;150:595-603.
66. Bauer JJ, Sesterhenn IA, Mostofi FK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996; 156:1511-1516. (Pubitemid 26307649)
67. Scherr DS, Vaughan ED Jr, Wei J, et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol. 1999;162:12-16; discussion 6-7.
68. Mackey TJ, Borkowski A, Amin P, et al. Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 1998;52:1085-1090. (Pubitemid 28533381)
69. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomized radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008; 9:342-351.
70. Li R, Younes M, Wheeler TM, et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate. 2004;58:193-199. (Pubitemid 38160907)
71. Richmond PJ, Karayiannakis AJ, Nagafuchi A, et al. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 1997;57:3189-3193. (Pubitemid 27351734)
72. Ding Z, Wu CJ, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;470: 269-273.
73. Wikström P, Stattin P, Franck-Lissbrant I, et al. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate. 1998;37:19-29. (Pubitemid 28385181)
74. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245-255.
75. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 2010;31:9-18.
76. Mucci LA, Powolny A, Giovannucci E, et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol. 2009;27:5627-5633.
77. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11-22.
78. Mosley JD, Keri RA. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genom. 2008;1:11.
79. Penney KL, Sinnott JA, Fall K, et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011;29: 2391-2396.
80. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329-340. (Pubitemid 351596394)
81. Wood DP Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol. 1997;15:3451-3457. (Pubitemid 27527717)
82. Berg A, Berner A, LillebyW, et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer. 2007;120:1603-1609. (Pubitemid 46399343)
83. Kollermann J, Weikert S, Schostak M, et al. Prognostic significance of disseminated tumor cells in the bone marrowof prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol. 2008;26: 4928-4933.
84. Kantoff PW, Halabi S, Farmer DA, et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol. 2001;19:3025-3028. (Pubitemid 32565439)
85. Ross RW, Manola J, Hennessy K, et al. Prognostic significance of baseline reverse transcriptaseYPCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin Cancer Res. 2005;11:5195-5198. (Pubitemid 41003706)
86. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:7053-7058. (Pubitemid 350276887)
87. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-6309.
88. Goodman OB Jr, Fink LM, Symanowski JT, et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev. 2009;18:1904-1913.
89. Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol. 2009;20:27-33.
90. Davis JW, Nakanishi H, Kumar VS, et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol. 2008; 179:2187-2191; discussion 91.
91. Stott SL, Lee RJ, Nagrath S, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010;2:25ra3.
92. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450:1235-1239.
93. Attard G, Swennenhuis JF, Olmos D, et al. Characterization o ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009;69: 2912-2918.
94. Leversha MA, Han J, Asgari Z, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res. 2009;15:2091-2097.
95. Holcomb IN, Grove DI, Kinnunen M, et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res. 2008;68:5599-5608.
96. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359: 366-377.
97. Bussemakers MJ, Van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975-5979. (Pubitemid 30004960)
98. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695-2698. (Pubitemid 34462754)
99. Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005;114: 950-956.
100. Vlaeminck-Guillem V, Ruffion A, Andre J, et al. Urinary prostate cancer 3 test: toward the age of reason? Urology. 2010;75:447-453.
101. Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008;180:1975-1978; discussion 8-9.
102. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia. 2006;8:885-888.
103. Rostad K, Hellwinkel OJ, Haukaas SA, et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS. 2009;117:575-582.
104. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007;13: 5103-5108. (Pubitemid 47502077)
105. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarkeranalysis of urine for he early detection of prostate cancer. Cancer Res. 2008;68:645-649. (Pubitemid 351206738)
106. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-914.
107. Haese A, Graefen M, Becker C, et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate. 2003;54:181-186. (Pubitemid 36120315)
108. Karazanashvili G, Abrahamsson PA. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol. 2003;169:445-457. (Pubitemid 36132962)
109. Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001;19:2856-2864. (Pubitemid 32538195)
110. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003;21: 3573-3579. (Pubitemid 46594048)
111. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-1184. (Pubitemid 41258223)
112. Liu J, Lau SK, Varma VA, et al. Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. ACS Nano. 2010;4:2755-2765.